ADVANCED METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Clinical trials for ADVANCED METASTATIC CASTRATION RESISTANT PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new ADVANCED METASTATIC CASTRATION RESISTANT PROSTATE CANCER trials appear
Sign up with your email to follow new studies for ADVANCED METASTATIC CASTRATION RESISTANT PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Hard-to-Treat prostate cancer? early trial launches
Disease control Recruiting nowThis study tests a new drug called INV-9956 in 84 men with advanced prostate cancer that has spread and stopped responding to hormone therapy and chemotherapy. The goal is to find a safe dose and see if the drug can shrink tumors or slow the disease. Participants take INV-9956 al…
Matched conditions: ADVANCED METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Ionova Life Sciences Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New drug cocktail targets Hard-to-Treat tumors
Disease control Recruiting nowThis study tests an experimental drug called AZD9574, taken alone or with other anti-cancer medicines, in about 695 people whose advanced solid tumors have grown despite prior treatment. The main goals are to check the drug's safety and find the right dose. Researchers will also …
Matched conditions: ADVANCED METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New radioactive drug targets Hard-to-Treat prostate cancer
Disease control Recruiting nowThis early-stage study tests a new drug, 225Ac-PSMA-Trillium, in people with advanced prostate cancer that has spread and no longer responds to hormone therapy. The drug delivers radiation directly to cancer cells to damage them. The main goals are to check safety, find the best …
Matched conditions: ADVANCED METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Bayer • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC